Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Member Viewpoints On Meeting Topics Should Be Part Of Vetting Process, GAO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Collecting information on committee member viewpoints ensures independence and impartiality in public eye, GAO report states. Committee nominees should be asked about public statements, participation in legal proceedings, previous research, GAO adds.

You may also be interested in...



Plan B GAO Investigation Sought By House Members

Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.

FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee

FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting

FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.

Topics

UsernamePublicRestriction

Register

PS059469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel